Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 12, 2023 06:30 ET | Source: Reviva Pharmaceuticals

Reviva Pharmaceuticals to Participate in the Lytham Partners Spring 2023 Investor Conference

CUPERTINO, Calif., May 12, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies...
May 11, 2023 06:30 ET | Source: Reviva Pharmaceuticals

Reviva Pharmaceuticals Announces Intent to File an IND for Brilaroxazine in Psoriasis After Promising Preclinical Data

Brilaroxazine topical liposomal-gel formulation (brilaroxazine lipogel) demonstrated proof-of-concept efficacy in the imiquimod-induced psoriatic mouse model IND submission for brilaroxazine lipogel...
May 04, 2023 06:00 ET | Source: Reviva Pharmaceuticals

Reviva Pharmaceuticals to Present at Three Upcoming Scientific Conferences in May 2023

CUPERTINO, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies...
May 01, 2023 16:01 ET | Source: Reviva Pharmaceuticals

Reviva Pharmaceuticals Presented Foundational Preclinical Data on Novel Serotonin-Dopamine Stabilizer Brilaroxazine at the 78th Annual SOBP and Publication in Medical Research Archives

Multifaceted activity of brilaroxazine supports potential for improvement in behavioral symptoms as well as accompanying neuroinflammation This proof-of-concept data supported the initial clinical...
April 25, 2023 07:00 ET | Source: Reviva Pharmaceuticals

Reviva Pharmaceuticals to Host Key Opinion Leader Event on Brilaroxazine (RP5063) in Phase 3 Clinical Trials for Schizophrenia

CUPERTINO, Calif., April 25, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies...
April 20, 2023 16:05 ET | Source: Reviva Pharmaceuticals

Reviva Pharmaceuticals to Present on Novel Serotonin-Dopamine Stabilizer Brilaroxazine at the 78th Annual Scientific Convention of the Society of Biological Psychiatry

CUPERTINO, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies...
March 30, 2023 07:30 ET | Source: Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc. Reports Full Year 2022 Financial Results and Recent Business Highlights

- Topline data for pivotal Phase 3 trial evaluating brilaroxazine for the treatment of schizophrenia remains on track for mid-2023 – - Completed majority of non-clinical and clinical...
March 07, 2023 08:00 ET | Source: Reviva Pharmaceuticals

Reviva Pharmaceuticals to Present at the 35th Annual Roth Conference

CUPERTINO, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies...
January 31, 2023 06:00 ET | Source: Reviva Pharmaceuticals

Reviva Pharmaceuticals to Present at the 2023 BIO CEO and Investor Conference

Cupertino, Calif., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies...
January 04, 2023 06:00 ET | Source: Reviva Pharmaceuticals

Reviva Pharmaceuticals Announces Letter to Shareholders

CUPERTINO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies...